PMID- 20024555
OWN - NLM
STAT- MEDLINE
DCOM- 20110802
LR  - 20211020
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 31
IP  - 4
DP  - 2011 Apr
TI  - Serum chemokines in patients with rheumatoid arthritis treated with etanercept.
PG  - 457-61
LID - 10.1007/s00296-009-1299-3 [doi]
AB  - Chemokines promote leucocyte traffic into the synovium, leading to the initiation 
      and progression of the rheumatoid arthritis (RA). The aim of the study was to 
      determine the effects of etanercept, a soluble tumour necrosis factor receptor 
      (sTNFr), on the serum chemokines levels in patients with active RA. Patients were 
      treated with 50 mg of subcutaneous injection of etanercept per week and 
      methotrexate (10-25 mg/week). Serum levels of interleukin-8 (IL-8), RANTES 
      (regulated upon activation, normal T cell expressed and secreted) and monocyte 
      chemoattractant protein-1 (MCP-1) were assessed by ELISA at months 0, 3, 6, 9 and 
      12, prior to injection. 3-month treatment with etanercept diminished serum 
      concentrations of IL-8, RANTES and MCP-1 (P < 0.05, P < 0.01 and P < 0.001, 
      respectively). Subsequent etanercept administrations prolonged decrease in serum 
      chemokines levels and in the case of IL-8 even intensified the reduction of its 
      concentration in serum. These changes were accompanied by significant decrease of 
      disease activity score (DAS28) (in all cases P < 0.001). Prior to the first 
      etanercept administration, serum concentrations of studied chemokines correlated 
      with markers of RA activity such as the erythrocyte sedimentation rate (ESR) and 
      DAS28. Following next drug injection such associations were less or not 
      significant. Therapy with etanercept and MTX not only caused a clinical 
      improvement but also diminished serum chemokines levels in RA patients. Further 
      treatment with etanercept sustained chemokines suppression.
FAU - Klimiuk, Piotr Adrian
AU  - Klimiuk PA
AD  - Department of Rheumatology and Internal Diseases, Medical University of 
      Bialystok, M.C. Sklodowskiej 24a, 15-276 Bialystok, Poland. klimp@umwb.edu.pl
FAU - Sierakowski, Stanislaw
AU  - Sierakowski S
FAU - Domyslawska, Izabela
AU  - Domyslawska I
FAU - Chwiecko, Justyna
AU  - Chwiecko J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091219
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Antirheumatic Agents)
RN  - 0 (CCL2 protein, human)
RN  - 0 (CCL5 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Chemokines)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Interleukin-8)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/immunology
MH  - Blood Sedimentation
MH  - Chemokine CCL2/blood
MH  - Chemokine CCL5/blood
MH  - Chemokines/*blood
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Interleukin-8/blood
MH  - Male
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
EDAT- 2009/12/22 06:00
MHDA- 2011/08/04 06:00
CRDT- 2009/12/22 06:00
PHST- 2009/10/02 00:00 [received]
PHST- 2009/11/29 00:00 [accepted]
PHST- 2009/12/22 06:00 [entrez]
PHST- 2009/12/22 06:00 [pubmed]
PHST- 2011/08/04 06:00 [medline]
AID - 10.1007/s00296-009-1299-3 [doi]
PST - ppublish
SO  - Rheumatol Int. 2011 Apr;31(4):457-61. doi: 10.1007/s00296-009-1299-3. Epub 2009 
      Dec 19.